Cumberland Pharmaceuticals (CPIX) Projected to Announce Quarterly Earnings on Tuesday

Posted by Francis Steltz on Jul 28th, 2026

Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) is expected to post its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Cumberland Pharmaceuticals to post earnings of ($0.13) per share and revenue of $8.5030 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) last issued its earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.The company had revenue of $9.13 million for the quarter, compared to analysts’ expectations of $8.50 million.

Cumberland Pharmaceuticals Stock Down 2.6%

NASDAQ CPIX traded down $0.18 during mid-day trading on Tuesday, hitting $6.85. The company’s stock had a trading volume of 52,938 shares, compared to its average volume of 515,436. The firm has a market capitalization of $102.60 million, a price-to-earnings ratio of -13.96 and a beta of 0.09. The company’s 50 day simple moving average is $6.20 and its 200 day simple moving average is $4.67. The company has a current ratio of 0.95, a quick ratio of 0.79 and a debt-to-equity ratio of 0.25. Cumberland Pharmaceuticals has a twelve month low of $1.85 and a twelve month high of $8.09.

Cumberland Pharmaceuticals Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, July 23rd will be issued a dividend of $1.50 per share.

Institutional Trading of Cumberland Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. XTX Topco Ltd purchased a new stake in Cumberland Pharmaceuticals in the 2nd quarter worth about $34,000. Bridgeway Capital Management LLC increased its stake in shares of Cumberland Pharmaceuticals by 2.3% in the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after purchasing an additional 4,200 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Cumberland Pharmaceuticals by 11.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after buying an additional 27,980 shares in the last quarter. Two Sigma Investments LP boosted its holdings in Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 5,326 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Cumberland Pharmaceuticals by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after buying an additional 5,653 shares during the period. 15.51% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CPIX. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen lowered Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

View Our Latest Analysis on CPIX

About Cumberland Pharmaceuticals

(Get Free Report)

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.